Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for a broad array of solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research Institute using unique medicinal chemistry to create a highly potent agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology studies have shown CT-262 to produce markedly better efficacy and surprisingly low toxicological effects compared to current first-line therapies in these nonclinical models. v